ArQule to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26, 2017
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, M.D., Head of
Research and Development and Chief Medical Officer, will present at the Cantor Fitzgerald Global Healthcare Conference on September
26th, 2017, at 10:20 a.m. ET at the InterContinental New York Barclay Hotel in New York, New York.
You can access the live webcast of the presentation via the “Investors & Media” section of our website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the
conclusion of the presentation.
About ArQule
ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat
cancers and rare diseases. ArQule’s mission is to discover, develop and commercialize novel small molecule drugs in areas of high
unmet need that will dramatically extend and improve the lives of our patients. Our clinical-stage pipeline consists of five drug
candidates, all of which are in targeted, biomarker-defined patient populations, making ArQule a leader among companies our size in precision medicine. ArQule’s proprietary pipeline includes: ARQ 087,
a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in phase 2 for
iCCA and in phase 1b for multiple oncology indications; ARQ 092, a selective inhibitor of the AKT serine/threonine kinase, in a
phase 1/2 company sponsored study for Overgrowth Diseases, in a phase 1 study for ultra-rare Proteus syndrome conducted by the
National Institutes of Health (NIH), as well as in multiple oncology indications; ARQ 751, a next generation AKT inhibitor, in
phase 1 for patients with AKT1 and PI3K mutations; and ARQ 761, a β-lapachone analog being evaluated as a promoter of NQO1-mediated
programmed cancer cell necrosis, in phase 1/2 in multiple oncology indications in partnership with the University of Texas
Southwestern Medical Center. In addition, we have advanced ARQ 531, an investigational, orally bioavailable, potent and reversible
inhibitor of both wild type and C481S-mutant BTK, in phase 1 for patients with B-cell malignancies refractory to other therapeutic
options. ArQule’s current discovery efforts are focused on the identification and development of novel kinase inhibitors,
leveraging the Company’s proprietary library of compounds. You can follow us on Twitter and LinkedIn.
ArQule
Dawn Schottlandt, 781-994-0300
Vice President, Investor Relations/ Corp. Communications
www.arqule.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170919005168/en/